New drug for narcolepsy! FDA approves unique cation hydroxybutyric acid therapy Xywav (sodium hydroxybutyrate magnesium potassium), reducing sodium intake by 92%!

The U.SFood and Drug Administration () has approved an oral solution (sodium hydroxybutylate, potassium, magnesium, calcium) for the treatment of denarcing or excessive daytime drowsiness in patients with narcolepsy (narcolepsy) and olderSeizuresleep (narcolepsy) is an incurable chronic neurological disease that has a profound impact on the health of patients over timeMany patients may experience years before getting a correct diagnosis can have a significant impact on their daily livesThe disease is a lifelong disease so it is important to have new options to help treat and collapseA hydroxybutyrate product with a unique cation component (sodium calcium magnesium potassium) has the same concentration of hydroxybutyrate but can be reduced by about night compared to the recommended dose range of grams of sodium hydroxybutyrateAlthough the exact mechanism of action is not yet known, the therapeutic effects of deorsisisanding and treatment are thought to be mediated by the effects of sleep on norepinephrine and dopamine-energy neurons as well as the hypothalamus cortexWarnings of high sodium content of sodium hydroxybutylate were previously the only approved products used to treat the collapse of patients with sexually transmitted diseases and were designated as the standard of care for inversion and treatment by the American Academy of Sleep Medicine ()Developed specifically to provide low-sodium hydroxybutyrate therapy for patients with seizure sleep and without warning about sodium levels, the drug will become a new standard of careIt is planned to be introduced to market by the end of the year following the implementation of the Risk Assessment and Disaster Reduction Strategy ()The United States Control (Special) Drug Administration () has classified as a class of controlled drugs and defines them as drugs with moderate or low physical and psychological dependenceThe approval was based on a global double-blind, placebo-controlled, randomized discontinued, multicenter study that demonstrated the effectiveness and safety of treating sudden inpatients with seizure sleepIn this study of the study, there was a highly statistically significant difference in the number of sudden seizures and the score of the sleepiness scale compared to placebos .There are a variety of dosing options available for adults and childrenThe prescription doctor can titby at different doses for the patient to take at nightThe initial therapeutic dose and protocol when the patient is switched from sodium hydroxybutyrate to treatment is the same as sodium hydroxybutyrate (by grams) and can be titrated as needed according to efficacy and tolerance"We've been developing for nearly a decade, and this is a unique hydroxybutarate product that significantly reduces sodium content," said the Chairman and CEO We are proud to advance the science behind the sleep research project to continue to make meaningful changes for patients with seizure sleep Lead researcher and clinical associate professor at the University of South Carolina School of Medicine said: "Approval of efficacy based on the efficacy demonstrated in clinical programs is important for patients who are experiencing the dystoctionassociats associated with seizure sleep disease This will allow patients to choose a low-sodium hydroxybutyric acid treatment This may help patients taking sodium hydroxybutylate better comply with the recommendations of the American Heart Association() for daily sodium intake The average American consumes too much sodium Excessive sodium intake is associated with elevated blood pressure, high blood pressure, stroke and other cardiovascular diseases () Original origin: ™